ExCellThera in the News

ExCellThera’s Safer Allogeneic Transplants

How ExCellThera is increasing the safety of allogeneic stem cell transplants ExCellThera Inc. is expanding cord blood into allogeneic stem cell transplants for cancer that have lower treatment-related mortality rates and GvHD incidence than competing technologies. Hematopoietic stem cell transplants (HSCTs) of unexpanded cord blood have two key drawbacks, according to CFO and Chief Legal Officer David Millette… BioCentury, December 14, 2019 (paywalled)

Dalton Pharma Services enters into a drug development and manufacturing services agreement with ExCellThera Inc.

Dalton Pharma Services, a leading North American pharmaceutical cGMP CDMO, is pleased to announce its drug development and manufacturing services agreement with ExCellThera Inc, an innovative biotechnology company focused on delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use. This agreement provides ExCellThera access to Dalton`s State-of-the-Art cGMP, Health Canada approved biopharmaceutical facility in Toronto, ON, Canada. Under the agreement terms… PRWeb, November 22, 2018

ExCellThera Founder and CEO, Guy Sauvageau, elected member of the Academy of Science, Royal Society of Canada

Dr. Guy Sauvageau, Principal Investigator at the Institute for Research in Immunology and Cancer (IRIC) of the Université de Montréal and hematologist at the Maisonneuve-Rosemont Hospital (CIUSSS de l’Est-de-l’Île-de-Montréal), has been elected a member of the Academy of Science of the Royal Society of Canada (RSC)… Markets Insider, September 11, 2018

Canadian cord-blood procedure passes key milestone in cancer trial

Researchers behind a made-in-Canada technology for multiplying the number of stem cells that can be derived from donated cord blood say they are ready to move on to the next phase in their effort to prove the technology can save lives… The Globe and Mail, June 27, 2018

Cancer: une molécule québécoise aux résultats «extraordinaires»

On connaît la multiplication des pains racontée dans les Évangiles. Mais voilà que des chercheurs québécois croient pouvoir sauver des vies grâce à un autre miracle : la multiplication des cellules souches dans le sang des cordons ombilicaux… La Presse, June 27, 2018

Start-ups – Des jeunes pousses déjà grandes

ExcellThera dévoilera sous peu les résultats de sa première étude clinique portant sur 25 patients atteints d’une forme de leucémie… La Presse, June 12, 2018

A molecule of hope: Université de Montréal researchers discover a method to increase quantity of cord blood stem cells

Umbilical cord blood, previously discarded, has been seen in more recent years as a useful source for blood stem cells. It contains haematopoietic stem cells that are usually…  Biotechnology Focus, May 2018.

Forging Partnerships In Regenerative Medicine Helps Make Canada A World Leader

Forging Partnerships In Regenerative Medicine Helps Make Canada A World Leader. Mediaplanet, April, 2017.

A multitiered approach to stem cell discoveries

A multitiered approach to stem cell discoveries. MaRS Magazine, November 4, 2016. 

The success of ExCellThera highlighted in Bio Business

Returning to form: New funding gives hope for 10 new therapies over the next 10 years Bio Business, Sept./Oct. 2015. 

ExCellThera in BioWorld Today

In the Clinic: ExCellThera. BioWorld Today (page 12), December 22, 2015.

U of T Expands Research Facilities in New Partnership with MaRS

U of T Expands Research Facilities in New Partnership with MaRS. Faculty of Medicine, University of Toronto, September 2, 2015.

Banking on cord blood

Banking on cord blood. Ontario Institute for Regenerative Medicine 

ExCellThera in the ten companies to watch – Stem Cell Assays

Ten companies to watch. Stem Cell Assays, July 1, 2015.

BiotechFinances: ExCellThera to transform stem cell transplantation therapies

Québec: ExCellThera veut transformer la greffe de cellules souches. BiotechFinances, June 22, 2015 [French only]